Follow on Google News News By Tag * Pain * Neuropathic * Clinical * Pipeline * Treatment * Trial * Drug * Candidates * Therapy * Therapies * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Now Available: "Neuropathic Pain - Extensive and diverse pipeline driven by high unmet need"Fast Market Research recommends "R&D Trends: Neuropathic Pain - Extensive and diverse pipeline driven by high unmet need" from Datamonitor, now available
Two key events occurred in the first half of 2011: Gralise (extended-release gabapentin; Depomed) obtained US Food and Drug Administration (FDA) approval for the treatment of post-herpetic neuralgia (PHN) in January 2011. Depomed expects to launch the drug in Q4 2011. Secondly, Horizant (gabapentin enacarbil; XenoPort/GlaxoSmithKline) Features and benefits * Analysis of key R&D dynamics in the drug development pipeline for neuropathic pain. * Evaluation of the target product profile for future neuropathic pain treatments. * Summary of clinical trial design in neuropathic pain. * Identification of the most innovative pharmacological targets in early-stage development. * Exploration of how the treatment landscape for neuropathic pain may change in the next 20 years. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Highlights The neuropathic pain pipeline is one of the most extensive in the central nervous system arena, and industry interest in has grown in recent years. Datamonitor considers this to be a reflection of the prevailingly high level of unmet need in the management of neuropathic pain. A wide variety of novel mechanisms of action are under investigation in the clinical pipeline, reflecting the heterogeneity of neuropathic pain conditions and the limitations in the current understanding of the most appropriate mechanisms to target. The future of neuropathic pain management will involve the increased use of combination therapies to provide optimum pain relief. Through increased understanding of the etiology of neuropathic pain conditions and the identification of biomarkers and likely responders to treatment, personalized therapy options will provide improved pain relief. Your key questions answered * How many drugs are in clinical development for the treatment of neuropathic pain? How does this compare to other pain indications? * What are the key trends in the neuropathic pain pipeline in terms of mechanisms of action under investigation and neuropathic subtypes being targeted? * What key companies are involved in the pipeline? What encourages and deters companies from investing in this area? * What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market? * How is the treatment of neuropathic pain likely to evolve over the next 10 to 20 years? Partial Table of Contents: Executive Summary Strategic scoping and focus Datamonitor key findings Related reports OVERVIEW Catalyst Summary CLINICAL PIPELINE OVERVIEW Datamonitor has identified 79 separate programs in clinical development Emerging features of the neuropathic pain pipeline Pipeline activity indicates substantial and growing industry interest Phase II is the most populous phase of development as candidates are assessed for a secondary indication Most commonly targeted indications include diabetic neuropathic pain and post-herpetic neuralgia Oral therapies dominate the pipeline A diverse range of target mechanisms are under investigation Companies involved in the neuropathic pain clinical pipeline Small, specialist pharmaceutical companies dominate the clinical pipeline Late-stage development compounds recently discontinued Three late-stage candidates in the neuropathic pain pipeline have been discontinued since 2009 TARGET PRODUCT PROFILE Lyrica (pregabalin; Pfizer's Lyrica is Datamonitor's comparator therapy for non-topical neuropathic pain treatments Clinical trial data for Lyrica Lidoderm (5% lidocaine patch; Endo/Grunenthal/ Endo's Lidoderm is Datamonitor's topical comparator therapy Clinical trial data for Lidoderm Target product profile versus current level of attainment Pipeline candidates need to address efficacy and side effects while being convenient and cost-effective Consequences of inadequately treated neuropathic pain CLINICAL TRIAL DESIGN IN NEUROPATHIC PAIN R&D approach differs depending on the geographic market in which approval is sought General neuropathic pain provides a broader customer base in the EU and Japan US approval requires evidence of efficacy and safety in each neuropathic pain subtype Typical trial design in neuropathic pain Although regulatory approval differs between regions, clinical trial design remains the same Choice of endpoint is the key clinical trial design factor in neuropathic pain Commonly used clinical trial endpoints in neuropathic pain A key challenge inherent in neuropathic pain clinical trials is recruitment of a homogenous, treatment-naive patient population Future developments in clinical trial design Selective patient recruitment will reduce costs while increasing the likelihood of demonstrating efficacy Although costly, head-to-head trials are of increasing importance to clarify efficacy INNOVATIVE EARLY-STAGE APPROACHES Gene expression inhibitors Background Clinical trials are required to confirm promising preclinical data Genetic approaches have the potential to target peripheral receptors devoid of central side effects Glial cell modulators Background Despite trial setbacks, glial cells provide numerous novel targets for the management of neuropathic pain Enkephalinase inhibitors Background Efficacy has yet to be demonstrated and the potential for central side effects remains a concern THE FUTURE OF TREATMENT IN NEUROPATHIC PAIN Use of combination therapies is expected to increase in the future Increasing use of combination therapies will provide more efficacious treatment options Pipeline candidates will benefit from improving upon the convenience of administration of available treatments Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number